Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder
Brief Summary: The purpose of this study was to examine how well two medicines (solifenacin succinate and mirabegron) combined work compared to each medicine alone in the treatment of bladder problems.


Options:
A: Arm Label: Fesoterodine; Type: EXPERIMENTAL; Interventions: Drug: fesoterodine fumarate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Tolterodine; Type: ACTIVE_COMPARATOR; Interventions: Drug: tolterodine tartrate | Intervention Type: DRUG; Name: fesoterodine fumarate; Assigned to Arm(s): Fesoterodine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: tolterodine tartrate; Assigned to Arm(s): Tolterodine
B: Arm Label: Botox A; Type: EXPERIMENTAL; Interventions: Drug: Botulinum toxin A (Botox A®) | Arm Label: Standardized Anticholinergic Regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Solifenacin 5mg, Drug: Solifenacin 10mg, Drug: Trospium chloride | Intervention Type: DRUG; Name: Botulinum toxin A (Botox A®); Assigned to Arm(s): Botox A | Intervention Type: DRUG; Name: Solifenacin 5mg; Assigned to Arm(s): Standardized Anticholinergic Regimen | Intervention Type: DRUG; Name: Solifenacin 10mg; Assigned to Arm(s): Standardized Anticholinergic Regimen | Intervention Type: DRUG; Name: Trospium chloride; Assigned to Arm(s): Standardized Anticholinergic Regimen
C: Arm Label: 1: Solifenacin 5 mg + Mirabegron 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Solifenacin succinate, Drug: Mirabegron, Drug: Placebo to match mirabegron | Arm Label: 2: Solifenacin 5 mg + Mirabegron 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Solifenacin succinate, Drug: Mirabegron, Drug: Placebo to match mirabegron | Arm Label: 3: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match solifenacin succinate, Drug: Placebo to match mirabegron | Arm Label: 4: Solifenacin 5 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Solifenacin succinate, Drug: Placebo to match mirabegron | Arm Label: 5:Mirabegron 25 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirabegron, Drug: Placebo to match solifenacin succinate, Drug: Placebo to match mirabegron | Arm Label: 6: Mirabegron 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirabegron, Drug: Placebo to match solifenacin succinate, Drug: Placebo to match mirabegron | Intervention Type: DRUG; Name: Solifenacin succinate; Assigned to Arm(s): 1: Solifenacin 5 mg + Mirabegron 25 mg, 2: Solifenacin 5 mg + Mirabegron 50 mg, 4: Solifenacin 5 mg | Intervention Type: DRUG; Name: Mirabegron; Assigned to Arm(s): 1: Solifenacin 5 mg + Mirabegron 25 mg, 2: Solifenacin 5 mg + Mirabegron 50 mg, 5:Mirabegron 25 mg, 6: Mirabegron 50 mg | Intervention Type: DRUG; Name: Placebo to match solifenacin succinate; Assigned to Arm(s): 3: Placebo, 5:Mirabegron 25 mg, 6: Mirabegron 50 mg | Intervention Type: DRUG; Name: Placebo to match mirabegron; Assigned to Arm(s): 1: Solifenacin 5 mg + Mirabegron 25 mg, 2: Solifenacin 5 mg + Mirabegron 50 mg, 3: Placebo, 4: Solifenacin 5 mg, 5:Mirabegron 25 mg, 6: Mirabegron 50 mg
D: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: Solifenacin succinate | Arm Label: II; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Solifenacin succinate; Assigned to Arm(s): I | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): II

Answer: C